DE69314339D1 - Auf proteinbasis beruhendes liefersystem - Google Patents

Auf proteinbasis beruhendes liefersystem

Info

Publication number
DE69314339D1
DE69314339D1 DE69314339T DE69314339T DE69314339D1 DE 69314339 D1 DE69314339 D1 DE 69314339D1 DE 69314339 T DE69314339 T DE 69314339T DE 69314339 T DE69314339 T DE 69314339T DE 69314339 D1 DE69314339 D1 DE 69314339D1
Authority
DE
Germany
Prior art keywords
pct
delivery system
date jan
phage
capsids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69314339T
Other languages
English (en)
Other versions
DE69314339T2 (de
Inventor
Peter Stockley
Robert Mastico
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
British Technology Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Technology Group Ltd filed Critical British Technology Group Ltd
Publication of DE69314339D1 publication Critical patent/DE69314339D1/de
Application granted granted Critical
Publication of DE69314339T2 publication Critical patent/DE69314339T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/18142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/804—Containing nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/806—Virus-based particle with exterior chemical attachment
    • Y10S977/808—Exterior attachment for targeting, e.g. drug targeting
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • AIDS & HIV (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Screw Conveyors (AREA)
  • Warehouses Or Storage Devices (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69314339T 1992-06-26 1993-06-25 Auf proteinbasis beruhendes liefersystem Expired - Fee Related DE69314339T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929213601A GB9213601D0 (en) 1992-06-26 1992-06-26 Protein based delivery system
PCT/GB1993/001338 WO1994000588A1 (en) 1992-06-26 1993-06-25 Protein based delivery system

Publications (2)

Publication Number Publication Date
DE69314339D1 true DE69314339D1 (de) 1997-11-06
DE69314339T2 DE69314339T2 (de) 1998-02-26

Family

ID=10717784

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69314339T Expired - Fee Related DE69314339T2 (de) 1992-06-26 1993-06-25 Auf proteinbasis beruhendes liefersystem

Country Status (12)

Country Link
US (1) US6159728A (de)
EP (1) EP0648272B1 (de)
JP (1) JP3634358B2 (de)
KR (1) KR100240515B1 (de)
AT (1) ATE158818T1 (de)
AU (1) AU679919B2 (de)
CA (1) CA2138414A1 (de)
DE (1) DE69314339T2 (de)
ES (1) ES2110097T3 (de)
GB (2) GB9213601D0 (de)
NZ (1) NZ253298A (de)
WO (1) WO1994000588A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4335025A1 (de) * 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytisch wirksame Partikel
DE19618797C2 (de) * 1996-05-10 2000-03-23 Bertling Wolf Vehikel zum Transport molekularer Substanz
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
EP0962525B1 (de) * 1996-08-09 2005-11-02 Dnavec Research Inc. Phage verbunden an ein nukleus lokalisierungssignal
WO1999066061A1 (fr) * 1998-06-18 1999-12-23 Dnavec Research, Inc. Phage de transfert d'acide nucleique
ATE417925T1 (de) 1999-07-20 2009-01-15 Morphosys Ag Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
AU2002347404A1 (en) * 2001-09-14 2003-04-01 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
DE60234375D1 (de) * 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
JP4658475B2 (ja) * 2001-11-07 2011-03-23 サイトス バイオテクノロジー アーゲー 骨疾患治療用の抗原アレイ
NZ537001A (en) * 2002-07-19 2007-04-27 Cytos Biotechnology Ag A composition comprising a virus-like particle and at least ghrelin or a ghrelin-derived peptide bound thereto
US7537767B2 (en) * 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US7517520B2 (en) * 2003-03-26 2009-04-14 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
US7959928B2 (en) 2004-10-05 2011-06-14 Cytos Biotechnology Ag VLP-antigen conjugates and their uses as vaccines
KR20070073896A (ko) * 2004-10-25 2007-07-10 사이토스 바이오테크놀로지 아게 위 억제 폴리펩티드(ｇｉｐ) 항원 어레이 및 그의 용도
WO2006095345A2 (en) * 2005-03-08 2006-09-14 Ramot At Tel-Aviv University Ltd. Targeted drug-carrying bacteriophages
PT1868642E (pt) * 2005-03-18 2013-07-10 Cytos Biotechnology Ag Proteínas de fusão de alergénios de gato e suas utilizações
CA2608579C (en) * 2005-05-26 2019-09-10 Cytos Biotechnology Ag Scalable fermentation process
NZ569741A (en) 2005-12-14 2012-02-24 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
SI2032592T1 (sl) 2006-06-12 2013-10-30 Cytos Biotechnology Ag Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov
EP2190987B1 (de) 2007-08-21 2012-11-14 MorphoSys AG Verfahren zur Formung von Disulphid-Bindungen
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
US9744183B2 (en) 2009-07-06 2017-08-29 Wave Life Sciences Ltd. Nucleic acid prodrugs and methods of use thereof
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
DK2734208T3 (en) 2011-07-19 2017-06-19 Wave Life Sciences Ltd PROCEDURES FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS
CN104684923B (zh) 2012-07-13 2018-09-28 株式会社新日本科学 手性核酸佐剂
RU2015104762A (ru) 2012-07-13 2018-08-31 Уэйв Лайф Сайенсес Лтд. Хиральный контроль
EP2872485B1 (de) 2012-07-13 2020-12-16 Wave Life Sciences Ltd. Asymmetrische hilfsgruppe
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
PT3094728T (pt) 2014-01-16 2022-05-19 Wave Life Sciences Ltd Desenho quiral
RU2695136C1 (ru) * 2018-06-19 2019-07-22 Общество с ограниченной ответственностью Биотехнология (ООО Биотехнология) Онколитический способ терапии рака молочной железы.
EP4141110A1 (de) 2020-04-24 2023-03-01 Obshchestvo S Ogranichennoy Otvetstvennost'yu "Ingenik" Verfahren zur herstellung von bakteriophagenteilchen der gattung levivirus
AU2022214170A1 (en) * 2021-01-27 2023-08-24 Aera Therapeutics, Inc. Pnma2-based capsids and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608850D0 (en) * 1986-04-11 1986-05-14 Diatech Ltd Packaging system
JPH06500232A (ja) * 1990-08-15 1994-01-13 サリオン・バイオロジクス・コーポレイシヨン 自己集合性複製欠陥型ハイブリッドウイルス粒子
WO1992006180A1 (en) * 1990-10-01 1992-04-16 University Of Connecticut Targeting viruses and cells for selective internalization by cells
US5298244A (en) * 1990-10-25 1994-03-29 University Of Saskatchewan Assembled viral particles and their use in a vaccine to rotaviral disease
GB9101550D0 (en) * 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
GB9114003D0 (en) * 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein

Also Published As

Publication number Publication date
US6159728A (en) 2000-12-12
KR950702248A (ko) 1995-06-19
JPH07508168A (ja) 1995-09-14
ATE158818T1 (de) 1997-10-15
AU679919B2 (en) 1997-07-17
AU4350793A (en) 1994-01-24
CA2138414A1 (en) 1994-01-06
GB2268492B (en) 1996-04-17
NZ253298A (en) 1996-03-26
JP3634358B2 (ja) 2005-03-30
EP0648272A1 (de) 1995-04-19
GB2268492A (en) 1994-01-12
ES2110097T3 (es) 1998-02-01
KR100240515B1 (ko) 2000-01-15
GB9213601D0 (en) 1992-08-12
EP0648272B1 (de) 1997-10-01
WO1994000588A1 (en) 1994-01-06
GB9313186D0 (en) 1993-08-11
DE69314339T2 (de) 1998-02-26

Similar Documents

Publication Publication Date Title
DE69314339D1 (de) Auf proteinbasis beruhendes liefersystem
DE69427650D1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
DE69428040D1 (de) Orale darreichungsform
MY132189A (en) Recombinant obese (ob) proteins
HRP20010877B1 (en) Composition for prevention and treatment of amyloidogenic disease
DE69412243D1 (de) Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
DE69326250D1 (de) Neuropeptide y antagoniste
DE69839489D1 (de) Impfstoff zur vorbeugung bzw. behandlung der hepatitis c
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
ATE408685T1 (de) Antimikrobielle peptide, abstammend von ubiquicidin
RS49520B (sr) Antimikrobno aktivne smeše
DE69102069D1 (de) 5-aminosalicylsäurederivate zur therapie chronisch entzündlicher baucherkrankungen.
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
ATE312179T1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
ES2097931T3 (es) Nueva proteina inhibidora de trombina a partir de chinches cazadoras.
NO962927L (no) Hestearteritt-virus peptider, antistoffer og deres anvendelse i en diagnostisk test
DE69325512D1 (de) Verwendung von remacemid zur behandlung des morbus parkinson
ES2094930T3 (es) Nueva proteina inhibidora de trombina aislada de garrapatas.
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.
ATE282704T1 (de) Isolierte und gereinigte humane lösliche guanylylcyclase alpha1/beta1 (hsgc alpha1/beta1)
YU8395A (sh) Protein sa tpo aktivnošću
NZ336371A (en) Human gene therapy using DNA/RNA cassette expression systems

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BTG INTERNATIONAL LTD., LONDON, GB

8339 Ceased/non-payment of the annual fee
8370 Indication related to discontinuation of the patent is to be deleted
8339 Ceased/non-payment of the annual fee